Trial Profile
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Petesicatib (Primary)
- Indications Unspecified
- Focus Pharmacodynamics
- Sponsors Roche
- 12 Feb 2021 Data from two studies (NCT02295332 [SAD] & NCT02521610 [MAD])) was used for pharmacokinetic analysis, published in the British Journal of Clinical Pharmacology.
- 01 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 17 Aug 2015 New trial record